Molecular Partners AG (MOLN)
3.87
+0.16
(+4.31%)
USD |
NASDAQ |
May 16, 16:00
Molecular Partners Cash from Operations (Quarterly): -17.00M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -17.00M |
| September 30, 2023 | -15.53M |
| June 30, 2023 | -15.32M |
| March 31, 2023 | -17.86M |
| December 31, 2022 | -13.22M |
| September 30, 2022 | -18.92M |
| Date | Value |
|---|---|
| June 30, 2022 | -20.63M |
| March 31, 2022 | 177.08M |
| December 31, 2021 | -21.50M |
| September 30, 2021 | -20.33M |
| June 30, 2021 | -24.65M |
| March 31, 2021 | -33.04M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-33.04M
Minimum
Mar 2021
177.08M
Maximum
Mar 2022
-3.409M
Average
-18.39M
Median
Cash from Operations (Quarterly) Benchmarks
| AC Immune SA | 1.172M |
| CRISPR Therapeutics AG | 109.75M |
| Addex Therapeutics Ltd | -0.5563M |
| NLS Pharmaceutics Ltd | -- |
| MoonLake Immunotherapeutics | -14.95M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 21.20M |
| Cash from Financing (Quarterly) | -0.3157M |
| Free Cash Flow | -66.61M |
| Free Cash Flow Per Share (Quarterly) | -0.5277 |
| Free Cash Flow to Equity (Quarterly) | -17.34M |
| Free Cash Flow to Firm (Quarterly) | -17.34M |
| Free Cash Flow Yield | -53.78% |